12:00 AM
 | 
May 11, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aflibercept: Phase III ongoing

Regeneron said it is has reached about 50% enrollment in 4 Phase III trials evaluating standard chemotherapy regimens with or without VEGF Trap. The VANILLA trial is evaluating VEGF Trap given once every 2 weeks in combination with gemcitabine as first-line treatment of metastatic pancreatic cancer; VELOUR...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >